Best Birth Control for Acne

Mechanism of Action of COCs for Acne

The American Academy of Dermatology notes that COCs treat acne through several anti-androgenic mechanisms, including decreasing ovarian androgen production 1, 2
COCs increase sex hormone-binding globulin, reducing free testosterone, as reported by the American Academy of Dermatology 1, 3
The mechanism of action of COCs also involves reducing 5α-reductase activity, according to the American Academy of Dermatology 1, 4
Block androgen receptor activation is another mechanism by which COCs treat acne, as noted by the American Academy of Dermatology 1, 2

FDA-Approved COCs for Acne Treatment

The FDA has approved four COCs for acne treatment in women who also desire contraception, including ethinyl estradiol/norgestimate, as reported by the American Academy of Dermatology 1, 3
Ethinyl estradiol/norethindrone acetate/ferrous fumarate is another FDA-approved COC for acne treatment, according to the American Academy of Dermatology 1, 3
Ethinyl estradiol/drospirenone/levomefolate is also an FDA-approved COC for acne treatment, as noted by the American Academy of Dermatology 1, 4

Safety Considerations

Venous Thromboembolism (VTE) Risk

The baseline VTE risk in non-pregnant, non-COC users is 1-5 per 10,000 woman-years, as reported by the American Academy of Dermatology 1, 3
The VTE risk with standard COCs is 3-9 per 10,000 woman-years, according to the American Academy of Dermatology 1, 3
The VTE risk with drospirenone-containing COCs is approximately 10 per 10,000 woman-years, as noted by the American Academy of Dermatology 1, 3
For context, the pregnancy VTE risk is 5-20 per 10,000 woman-years, as reported by the American Academy of Dermatology 1, 3

Other Safety Considerations

COCs are associated with small increases in myocardial infarction and stroke risks, particularly in women over 35 who smoke, as noted by the American Academy of Dermatology 1, 5
COCs are also associated with small increases in myocardial infarction and stroke risks in women with hypertension, diabetes, or migraines, according to the American Academy of Dermatology 1, 5
Contraindications for COCs include pregnancy, current breast cancer, history of deep vein thrombosis or pulmonary embolism, ischemic heart disease, severe liver disease, and migraine with aura at any age or without aura if ≥35 years, as reported by the American Academy of Dermatology 6

Clinical Decision Algorithm

The American Academy of Dermatology recommends drospirenone-containing COCs as the first-line option for women with moderate acne who also desire contraception 1
Alternative options for women who cannot take drospirenone include norgestimate-containing COCs and norethindrone acetate-containing COCs, as noted by the American Academy of Dermatology 1
Progestin-only contraceptives should be avoided as they may worsen acne, according to the American Academy of Dermatology 1, 4

Important Caveats

COCs should only be used for acne in women who also desire contraception, as noted by the American Academy of Dermatology 3
A comprehensive medical history and blood pressure measurement should be performed before prescribing COCs, according to the American Academy of Dermatology 5, 7
All COCs have a net anti-androgenic effect when combined with estrogen, regardless of progestin type, as reported by the American Academy of Dermatology 1, 3

Hormonal Acne Treatment Guidelines

First-Line Treatment Options

The American Academy of Dermatology recommends combined oral contraceptives (COCs) containing drospirenone as the first-line treatment option for women with hormonal acne who also desire contraception 8
For women with hormonal acne who do not need contraception, spironolactone is the preferred treatment option, with a dosage of 50-100 mg daily being effective and having favorable tolerability 9
The use of COCs can lead to acne improvement in 3-6 months, and can be used alone or in combination with other acne treatments, benefiting women with or without clinical signs of hyperandrogenism 9
Spironolactone has potent antiandrogen activity and can be used as monotherapy or adjunctive therapy, with 66% of women achieving clear or markedly improved skin 9

Treatment Algorithm

For women desiring contraception, the first choice is drospirenone-containing COC, and for inadequate response after 3-6 months, spironolactone 50-100 mg daily can be added 9, 10
For women not desiring contraception, the first choice is spironolactone 50-100 mg daily, and for inadequate response, topical treatments such as retinoids or benzoyl peroxide can be considered 8, 9, 10, 11

Topical Treatment Options

Topical retinoids, benzoyl peroxide, and fixed-dose combinations of retinoids with benzoyl peroxide can be used as adjuncts to hormonal therapy for women with hormonal acne 8, 11
Clascoterone, a topical antiandrogen, can also be used as an adjunct to hormonal therapy 8

Important Safety Considerations

Progestin-only contraceptives should be avoided as they may worsen acne, and COCs should not be withheld from appropriate candidates due to misconceptions about antibiotic interactions 9, 10
Routine potassium monitoring is not required in young, healthy women on spironolactone without risk factors for hyperkalemia 10

Monitoring and Follow-up

Blood pressure measurement should be taken before initiating COCs, and follow-up should be done at 3 months to assess initial response and side effects, and at 6 months to assess maximal benefit 9, 10
Potassium monitoring should be considered only in patients with risk factors for hyperkalemia, such as renal insufficiency, heart failure, or concomitant medications like ACE inhibitors 10

Timeline for Acne Improvement with Combined Oral Contraceptives

Expected Timeline for Clinical Response

Statistically significant improvement in acne becomes evident by the end of cycle 3 (approximately 3 months) compared to placebo in randomized controlled trials, according to the American Academy of Dermatology 12, 13
Patients should be counseled that acne reduction may not be appreciated during the first few months of treatment, as recommended by the American Academy of Dermatology 12, 13
Early combination with other acne medications (topical retinoids, benzoyl peroxide) is appropriate during this initial period to provide more immediate benefit, as suggested by the American Academy of Dermatology 12, 13

Mechanism Explaining Delayed Response

Combined oral contraceptives decrease free testosterone by 40-50% on average, but this hormonal effect requires time to translate into visible acne improvement, according to the American Academy of Dermatology 14, 15, 16
Estrogen reduces conversion of testosterone to dihydrotestosterone in the pilosebaceous unit, decreasing sebum production gradually over months, as explained by the American Academy of Dermatology 14, 15, 16

Important Clinical Considerations

Explicitly counsel patients at initiation that visible improvement will take several months to prevent premature discontinuation, as recommended by the American Academy of Dermatology 12, 13
Common side effects (breakthrough bleeding, nausea, breast tenderness) tend to resolve within the first 2-3 cycles, often before acne improvement becomes apparent, according to the American Academy of Dermatology 14, 15, 16

Comparative Effectiveness Between COC Types

Drospirenone-containing COCs may show slightly superior efficacy compared to other progestins in head-to-head trials, as reported by the American Academy of Dermatology 14, 15, 16

Hormonal Acne and Endometriosis Treatment with Drospirenone-Containing Formulations

FDA-Approved Formulations for Acne

The American Academy of Dermatology recommends ethinyl estradiol 30 mcg/drospirenone 3 mg (21/7 regimen) as a first-line treatment for women with moderate acne who also desire contraception, with significant reductions in acne symptoms observed by cycle 3 (approximately 3 months) 17, 18
Ethinyl estradiol 20 mcg/drospirenone 3 mg/levomefolate (24/4 regimen) is also FDA-approved for acne treatment in women, providing a net anti-androgenic effect when combined with estrogen, regardless of progestin type 17, 18

Safety Considerations for Combined Drospirenone COCs

The American Academy of Dermatology notes that absolute contraindications for combined drospirenone COCs include renal dysfunction or adrenal insufficiency, current or history of deep vein thrombosis or pulmonary embolism, breast cancer or estrogen/progestin-sensitive cancers, hepatic dysfunction or tumors, uncontrolled hypertension, smoking if ≥35 years of age, and migraine with aura at any age, or migraine without aura if ≥35 years 18
Baseline monitoring before COC initiation should include a comprehensive medical history, blood pressure measurement, pregnancy test, and baseline potassium level, with potassium monitoring recommended at 4-6 weeks after starting therapy to minimize the risk of hyperkalemia 18

Switching from Spironolactone to Birth Control for Acne

Introduction to Drospirenone-Containing Pills

The American Academy of Dermatology recommends switching to a combined oral contraceptive containing drospirenone, such as Yaz or Yasmin, which is FDA-approved for acne treatment, due to its unique anti-androgenic properties similar to spironolactone 19, 20
Drospirenone decreases ovarian androgen production, increases sex hormone-binding globulin, reduces 5-alpha-reductase activity, and blocks androgen receptor activation, making it an effective replacement for spironolactone 19, 20

Efficacy of Drospirenone-Containing Pills

Drospirenone-containing COCs demonstrate superior efficacy compared to other progestin formulations, including norgestimate and levonorgestrel, in head-to-head comparisons 19, 20
The American Academy of Dermatology suggests that drospirenone 3 mg/ethinyl estradiol (either 20 or 30 mcg formulation) is a first-line option, showing significant reductions in inflammatory, non-inflammatory, and total acne lesions 19

Timeline Expectations

Visible acne improvement requires 3-6 months of continuous therapy with drospirenone-COCs, with statistically significant improvement typically evident by the end of cycle 3 (approximately 3 months) 21
The American Academy of Dermatology recommends continuing topical acne treatments, such as retinoids and benzoyl peroxide, during the first 2-3 months to provide more immediate benefit while waiting for the COC to take full effect 21

Safety Considerations

Drospirenone has mild potassium-sparing diuretic effects, but multiple large retrospective studies found no increased risk of hyperkalemia with drospirenone-COCs compared to other COCs 19, 21
Routine potassium monitoring is not required in young, healthy women without kidney, liver, or adrenal disease 22
The American Academy of Dermatology notes that absolute contraindications for drospirenone-COCs include kidney, liver, or adrenal disease, current or history of deep vein thrombosis or pulmonary embolism, current breast cancer, smoking if ≥35 years of age, and migraine with aura at any age 20
Venous thromboembolism (VTE) risk with drospirenone-COCs is approximately 10 per 10,000 woman-years, compared to 3-9 per 10,000 woman-years for standard COCs and 1-5 per 10,000 woman-years for non-users 19, 20

Alternative Options

If drospirenone is contraindicated, the American Academy of Dermatology recommends choosing ethinyl estradiol/norgestimate (Ortho Tri-Cyclen) as a second-line option, which is also FDA-approved for acne and showed reduced total lesion counts in combined trials 19, 20
The American Academy of Dermatology advises against prescribing progestin-only contraceptives for acne, as they consistently worsen acne 21

Contraception for Cystic Acne

Initiation and Monitoring

The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends starting the COC anytime if reasonably certain the patient is not pregnant, and if starting >5 days after menses began, use backup contraception for 7 days 23
Before prescribing, obtain a comprehensive medical history focusing on VTE risk factors, cardiovascular disease, migraine characteristics, liver disease, and smoking status, and measure blood pressure, as recommended by the MMWR Recommendations and Reports 23

Treatment Expectations

The American Academy of Dermatology recommends continuing or adding topical acne treatments for the first 2-3 months to provide more immediate benefit while waiting for the COC's full effect 24
Visible acne improvement requires 3-6 months of continuous therapy, with statistically significant improvement evident by cycle 3, as reported in the Journal of the American Academy of Dermatology 24

Safety Considerations

The MMWR Recommendations and Reports notes that with a normal BMI, there are no obesity-related contraindications, but screen for absolute contraindications such as renal dysfunction, deep vein thrombosis, or pulmonary embolism 23

Acne Treatment with Combined Oral Contraceptives

FDA-Approved Options

The American Academy of Dermatology recommends prescribing a combined oral contraceptive containing drospirenone 3 mg with ethinyl estradiol (either 20 or 30 mcg) for women with acne who also desire contraception, as it demonstrates superior anti-androgenic effects compared to other formulations 25
Drospirenone has unique anti-androgenic properties, decreasing ovarian androgen production, increasing sex hormone-binding globulin, reducing 5-alpha-reductase activity, and blocking androgen receptor activation, leading to significant reductions in inflammatory, non-inflammatory, and total acne lesions compared to placebo 25
The American Academy of Dermatology suggests that ethinyl estradiol/norgestimate (Ortho Tri-Cyclen) is FDA-approved for acne and represents the best alternative if drospirenone is contraindicated 25
Ethinyl estradiol/norethindrone acetate/ferrous fumarate is FDA-approved for acne treatment and shows better results for clinician global assessment of no acne to mild acne 25

Critical Timeline Expectations

The American Academy of Dermatology advises counseling patients that visible improvement requires 3-6 months of continuous therapy, with statistically significant improvement typically evident by the end of cycle 3 (approximately 3 months) 25

Absolute Contraindications

The American Academy of Dermatology states that current or history of deep vein thrombosis or pulmonary embolism is a contraindication for combined oral contraceptives 25
Current breast cancer or estrogen/progestin-sensitive cancers are contraindications for combined oral contraceptives 25
Severe liver disease, hepatic dysfunction, or liver tumors are contraindications for combined oral contraceptives 25
Uncontrolled hypertension is a contraindication for combined oral contraceptives 25
Smoking if ≥35 years of age is a contraindication for combined oral contraceptives 25
Migraine with aura at any age, or migraine without aura if ≥35 years is a contraindication for combined oral contraceptives 25
Ischemic heart disease is a contraindication for combined oral contraceptives 25

Safety Considerations: VTE Risk in Perspective

The baseline VTE risk in non-pregnant, non-COC users is 1-5 per 10,000 woman-years, while drospirenone-containing COCs have an approximate VTE risk of 10 per 10,000 woman-years 25
Standard COCs have a VTE risk of 3-9 per 10,000 woman-years 25
Pregnancy VTE risk is 5-20 per 10,000 woman-years, and postpartum (within 12 weeks) VTE risk is 40-65 per 10,000 woman-years 25

Required Pre-Treatment Evaluation

A comprehensive medical history focusing on VTE risk factors, cardiovascular disease, migraine characteristics, liver disease, and smoking status is necessary before prescribing combined oral contraceptives 25
Blood pressure measurement is mandatory before prescribing combined oral contraceptives 25

CDC Guideline Recommendations for Continuous Drospirenone‑Containing Combined Oral Contraceptives in Women with Hormonal Acne and Endometriosis

Regimen Modification

The 24‑day active/4‑day placebo (24/4) regimen of drospirenone 3 mg/ethinyl estradiol 20 µg can be converted to a truly continuous schedule by omitting the placebo pills and starting a new pack immediately after the 24 active pills 26.

Pre‑treatment Evaluation

Prior to initiating therapy, a mandatory blood‑pressure measurement should be obtained to screen for hypertension 26.

Women aged ≥ 35 years who smoke should not be prescribed drospirenone‑containing COCs because of increased thrombotic risk 26.
A history of ischemic heart disease is an absolute contraindication to drospirenone‑containing COCs 26.

Initiation Protocol & Backup Contraception

If therapy is started more than 5 days after the onset of menses, patients should use a non‑hormonal backup method (e.g., condoms) for the first 7 consecutive days 26.
For continuous use, patients are instructed to skip the four placebo pills and begin a new pack immediately after completing the 24 active pills 26.

Management of Unscheduled Bleeding with Continuous Use

Unscheduled spotting or bleeding is the most common adverse effect of continuous regimens; it is generally benign and tends to diminish over the first 3–6 months of therapy 26.
If bleeding persists and is bothersome after the first 21 days of continuous use, a short hormone‑free interval of 3–4 days may be introduced (no more than once per month) to improve tolerability while maintaining contraceptive efficacy 26.
When unscheduled bleeding remains unacceptable despite the above measures, clinicians should consider switching to an alternative contraceptive method 26.

Monitoring and Follow‑Up Schedule

A follow‑up visit at 3 months should assess the initial therapeutic response, side‑effects (including breakthrough bleeding, nausea, breast tenderness), and repeat blood‑pressure measurement 26.
Hormone‑free intervals should be limited to no more than one per month, as more frequent interruptions can reduce contraceptive effectiveness and may allow recurrence of endometriosis‑related symptoms 26.